From Discovery to Impact: Celebrating 30 years of BRCA1 and BRCA2

This hybrid event will highlight research and innovation related to the discovery of the BRCA1 and BRCA2 genes, including the work of Dr. Steven Narod, Senior Scientist at Women’s College Hospital Research and Innovation Institute, who contributed to their discovery. The event will showcase the progress our team has made since the discovery of these genes.

We are pleased to welcome guests both:

NOV 4, 2024 (day 1): RESEARCHERS & HEALTH PROFESSIONALS

• Doors Open: 8:30 a.m.
• Program Begins: 9:00 a.m.
• Closing Reception: 3:45 p.m.

NOV 5, 2024 (day 2): PATIENTS & THE PUBLIC

• Doors Open: 9:30 a.m.
• Program Begins: 10:00 a.m.
• Closing Reception: 3:00 p.m.

WHO SHOULD ATTEND THIS HYBRID EVENT

Nov 4 (day 1): Physicians and other healthcare providers, genetic counsellors, researchers and other professionals or trainees working in the prevention, detection and treatment of of BRCA-associated cancers.

Nov 5 (day 2): Individuals or families who carry a BRCA mutation or may be affected by a genetic mutation associated with an increased risk of breast or ovarian cancer.

WHY ATTEND

Dr. Steven Narod, Senior Scientist at Women’s College Hospital Research and Innovation Institute, was part of the team that made this important medical breakthrough. He and the Hereditary Cancer Research Unit at Women's College Hospital have continued to make significant impacts on the management of individuals at high-risk of developing breast and ovarian cancers.

At this event, we will highlight findings from 30 years of research and innovation including:

• establishing the effectiveness of cancer risk reduction surgeries,
• treatment of BRCA-associated breast cancer,
• contributions to national and international guidelines that inform care across the globe,
• and much more!

A light meal and refreshments will be served to in-person attendees.

REGISTRATION FEE: $25 (in-person) or $15 (virtual)

Please note: Tickets are non-refundable

This event is hosted by The Peter Gilgan Centre for Women’s Cancers at Women’s College Hospital with support from AstraZeneca and Merck.

The receptions are hosted by Women's College Hospital Foundation.

Host or Publisher Hereditary Breast & Ovarian Cancer Research Unit